CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats.

Publisher: Springer Country of Publication: Germany NLM ID: 9804161 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1522-1709 (Electronic) Linking ISSN: 15209512 NLM ISO Abbreviation: Sleep Breath Subsets: MEDLINE

Publication: 2005- : Heidelberg ; New York : Springer
Original Publication: Titisee-Neustadt, Germany : Druckbild GmbH,

Bone Diseases, Metabolic/*physiopathology ; Cannabinoid Receptor Antagonists/*administration & dosage ; Hypoxia/*physiopathology ; Protective Agents/*administration & dosage ; Receptor, Cannabinoid, CB1/*antagonists & inhibitors ; Receptor, Cannabinoid, CB1/*metabolism ; Rimonabant/*administration & dosage; Animals ; Bone Diseases, Metabolic/drug therapy ; Bone Diseases, Metabolic/metabolism ; Disease Models, Animal ; Male ; Osteoclasts/drug effects ; Osteoclasts/metabolism ; Rats, Sprague-Dawley ; Tartrate-Resistant Acid Phosphatase/blood

Objective: The endocannabinoid system (ECS) regulates bone turn-over and remodeling. Chronic intermittent hypoxia (CIH) occurring during obstructive sleep apnea (OSA) may lead to disorders of the ECS and bone metabolism abnormalities. This study aimed to investigate whether or not the cannabinoid receptor 1 (CB1R) antagonist rimonabant (Ri) alleviates bone metabolism abnormalities and bone destruction induced by chronic intermittent hypoxia (CIH).
Methods: Healthy male Sprague Dawley (SD) rats (n=48) were randomly divided into 6 groups of 8 rats: 2 normal control (NC) groups, 2 intermittent hypoxia (IH) groups, and 2 IH + Ri groups. Rats in NC groups breathed room air for 4 weeks (4w NC group) and 6 weeks (6w NC group). Rats in IH groups experienced IH environment for 4 weeks (4w IH group) and 6 weeks (6w IH group). In addition to the same IH exposure, rats in IH + Ri group were given daily intraperitoneal injection of Ri at the dosage of 1.5 mg/kg/d for 4 weeks (4w IH + Ri group) and 6 weeks (6w IH + Ri group). Levels of serum tartrate-resistant acid phosphatase (TRAP, a marker of bone resorption) were determined by ELISA. Hematoxylin and eosin (HE) staining was performed on bone sections to observe the changes in bone microstructure. Expression of CB1R in bone tissue was determined by immunohistochemistry.
Results: TRAP levels were higher in the 4w IH and 6w IH groups than in the 4w NC and 6w NC groups; TRAP levels were lower in the 4w IH + Ri and 6w IH + Ri groups than in the 4w IH and 6w IH groups. HE staining showed that the morphology of bone cells in the NC group was normal, but the 4w IH group had mild edema of bone cells, reduction in trabecular bone, and destruction of bone microstructure. Changes were more severe in the 6w IH group than 4w IH. The 4w IH + Ri group was slightly improved compared with the 4w IH group. The 6w IH + Ri group was improved compared with the 4w IH + Ri group. The results of immunohistochemistry showed that the expression of CB1R in IH group was significantly higher than that in NC group. The expression of CB1R in the IH + Ri group was lower than that in the IH group. With the prolongation of hypoxia, the expression of CB1R in bone cells of IH group increased. The expression level of CB1R in IH + Ri group decreased with the prolongation of intervention time. Correlation analysis showed that the expression rate of CB1R in bone cells was positively correlated with the level of TRAP in serum.
Conclusion: CIH increases serum TRAP levels and triggers metabolic bone disorder by activating bone CB1R. Intervention with CB1R antagonist (rimonabant) reduces the bone dysmetabolism in the CIH rat model.

PLoS One. 2014 Mar 12;9(3):e89566. (PMID: 24622769)
Calcif Tissue Int. 2017 Jul;101(1):92-101. (PMID: 28303318)
Acta Otorhinolaryngol Ital. 2015 Dec;35(6):420-5. (PMID: 26900248)
Biomed Res Int. 2016;2016:9782031. (PMID: 26904688)
J Clin Sleep Med. 2017 Mar 15;13(3):479-504. (PMID: 28162150)
Sleep Med. 2010 May;11(5):441-6. (PMID: 20362502)
Aging Cell. 2017 Oct;16(5):1051-1061. (PMID: 28752643)
Cannabis Cannabinoid Res. 2016 Jan 01;1(1):3-15. (PMID: 28861474)
Int J Neurosci. 2018 Sep;128(9):797-804. (PMID: 29264962)
Lancet Respir Med. 2015 Apr;3(4):310-8. (PMID: 25682233)
Trends Pharmacol Sci. 2015 May;36(5):277-96. (PMID: 25796370)
Diabetes Metab Syndr Obes. 2016 Aug 25;9:281-310. (PMID: 27601926)
PLoS One. 2015 Jul 06;10(7):e0132342. (PMID: 26147647)
Br J Pharmacol. 2012 Apr;165(8):2584-97. (PMID: 21649637)
Sleep Med. 2009 Sep;10(8):913-8. (PMID: 19307155)
PLoS One. 2015 Sep 28;10(9):e0136546. (PMID: 26414859)
PLoS One. 2014 Aug 22;9(8):e105555. (PMID: 25148040)
Sleep. 2017 Sep 1;40(9):. (PMID: 28934522)
Acta Otorhinolaryngol Ital. 2015 Apr;35(2):69-74. (PMID: 26019388)
J Bone Miner Metab. 2016 Jul;34(4):475-81. (PMID: 26204846)
Bone. 2018 Mar;108:34-42. (PMID: 29274505)
Evid Based Complement Alternat Med. 2015;2015:238482. (PMID: 26664449)
JAMA. 2017 Jan 24;317(4):407-414. (PMID: 28118461)
Anesth Analg. 2017 Jan;124(1):179-191. (PMID: 27861433)
Sleep Med Rev. 2017 Aug;34:70-81. (PMID: 27568340)

No. 81870076 National Natural Science Foundation of China (CN); No. 81570086 National Natural Science Foundation of China; No. 2017‑120 Shanxi Scholarship Council of China; No. 2017-Key 6 Shanxi Scholarship Council of China; No. 201703D421027 Shanxi Province Science and Technology Department; No. 2017048 Health and Family Planning Commission of Shanxi Province

Keywords: Cannabinoid receptor 1 (CB1R); Chronic intermittent hypoxia (CIH); Obstructive sleep apnea syndrome (OSAS); Rimonabant (Ri); Tartrate-resistant acid phosphatase (TRAP)

0 (Cannabinoid Receptor Antagonists)
0 (Cnr1 protein, rat)
0 (Protective Agents)
0 (Receptor, Cannabinoid, CB1)
EC 3.1.3.2 (Tartrate-Resistant Acid Phosphatase)
RML78EN3XE (Rimonabant)

Date Created: 20200104 Date Completed: 20211123 Latest Revision: 20211123

20221213

PMC7679350

10.1007/s11325-019-02009-9

31898189